---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000010"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:20:05.936759+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer

## Summary
- FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.
- Median overall survival improved to 16.2 months vs 14.2 months (HR 0.82, p=0.039).
- Time to pain progression extended by 6.1 months (15.2 vs 9.1 months).
- First new treatment approved for locally advanced pancreatic cancer in nearly 30 years.
- Optune Pax well-tolerated; most adverse events were mild-to-moderate skin reactions under arrays.

## SEC filing metadata
- accession: 0001645113-26-000010
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000010/0001645113-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000010/nvcr-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000010
- JSON: https://secwatch.observer/filing/0001645113-26-000010.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.